U.S. FDA extends review of Exelixis' cancer drug

EXEL•2026-09-11

FDA adds three months to Exelixis review

Sept. 11 (Reuters) - The U.S. Food and Drug Administration has extended the review of Exelixis' experimental colorectal cancer drug combination by three months, the company said in a filing on Friday.

The regulator will now make its decision by March 3, 2027.

U.S. FDA extends review of Exelixis' cancer drug

FDA adds three months to Exelixis review

Related News

Peraso showcases 60 GHz mmWave drone communications at UAV Technology Conference

Olin-Huntsman merger clears US HSR antitrust waiting period

Kroger down after cutting annual sales forecast

NetApp Inc <NTAP.O>: Argus Research raises target price to $225 from $250

Elanco sets third-quarter results release, conference call